One of the big market stories of 2023 has been the sudden rise of GLP-1 weight loss and diabetes drugs. Healthcare is not normally a sector we associate with high volatility: that has changed this year. Hype around the potentially massive opportunity for GLP-1 drugs has seen the stock prices of their developers, Novo Nordisk and Eli Lilly, soar.
- Market: International
- Sector: Healthcare
9 November 2023